Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus.
Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus.
复制标题
DOI:
10.1021/cb100269f
复制
发表时间:
2011-01-21
影响因子:
4
通讯作者:
Walker, Suzanne
中科院分区:
文献类型:
--
作者:
Campbell, Jennifer;Singh, Atul K.;Maria, John P. Santa, Jr.;Kim, Younghoon;Brown, Stephanie;Swoboda, Jonathan G.;Mylonakis, Eleftherios;Wilkinson, Brian J.;Walker, Suzanne
Methicillin resistance in Staphylococcus aureus depends on the production of mecA, which encodes penicillin-binding protein 2A (PBP2A), an acquired peptidoglycan transpeptidase (TP) with reduced susceptibility to beta-lactam antibiotics. PBP2A crosslinks nascent peptidoglycan when the native TPs are inhibited by beta-lactams. Although mecA expression is essential for beta-lactam resistance, it is not sufficient. Here we show that blocking the expression of wall teichoic acids (WTAs) by inhibiting the first enzyme in the pathway, TarO, sensitizes MRSA strains to beta-lactams even though the beta-lactam-resistant transpeptidase, PBP2A, is still expressed. The dramatic synergy between TarO inhibitors and beta-lactams is noteworthy not simply because strategies to overcome methicillin-resistant S. aureus (MRSA) are desperately needed, but because neither TarO nor the activities of the native TPs are essential in MRSA strains. The “synthetic lethality” of inhibiting TarO and the native TPs suggests a functional connection between ongoing WTA expression and peptidoglycan assembly in S. aureus. Indeed, transmission electron microscopy shows that S. aureus cells blocked in WTA synthesis have extensive defects in septation and cell separation, indicating dysregulated cell wall assembly and degradation. Our studies imply that WTAs play a fundamental role in S. aureus cell division and raise the possibility that synthetic lethal compound combinations may have therapeutic utility for overcoming antibiotic resistant bacterial infections.
登录
查看更多内容
影响因子:
3.2
作者:
McAleese, F;Wu, SW;Tomasz, A
通讯作者:
Tomasz, A
影响因子:
3.2
作者:
BECK, WD;BERGERBACHI, B;KAYSER, FH
通讯作者:
KAYSER, FH
影响因子:
--
作者:
Huber, Joann;Donald, Robert G. K.;Roemer, Terry
通讯作者:
Roemer, Terry
影响因子:
3.2
作者:
Gründling, A;Schneewind, O
通讯作者:
Schneewind, O
影响因子:
3.6
作者:
Pinho, MG;Errington, J
通讯作者:
Errington, J